OTCPK:IMPZ.Y

Stock Analysis Report

Executive Summary

Implanet S.A. provides various spine, knee, and arthroscopy orthopedic implants in France, the United States, Brazil, and internationally.

Snowflake

Fundamentals

Imperfect balance sheet with limited growth.

Risks

  • Implanet is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Implanet's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IMPZ.Y

1.1%

US Medical Equipment

-0.5%

US Market


1 Year Return

-15.5%

IMPZ.Y

7.9%

US Medical Equipment

0.9%

US Market

IMPZ.Y underperformed the Medical Equipment industry which returned 11.4% over the past year.

IMPZ.Y underperformed the Market in United States of America which returned -1.1% over the past year.


Share holder returns

IMPZ.YIndustryMarket
7 Day0%1.1%-0.5%
30 Day0%3.1%4.8%
90 Day0%3.6%2.3%
1 Year-15.5%-15.5%8.8%7.9%3.1%0.9%
3 Yearn/a70.9%65.8%45.5%36.0%
5 Yearn/a139.2%112.0%62.5%44.7%

Price Volatility Vs. Market

How volatile is Implanet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Implanet undervalued based on future cash flows and its price relative to the stock market?

1.06x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Implanet to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Implanet to establish if it is available at substantial discount.


Price Based on Earnings

Implanet is loss making, we can't compare its value to the US Medical Equipment industry average.

Implanet is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Implanet, we can't assess if its growth is good value.


Price Based on Value of Assets

Implanet is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Implanet expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

28.8%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Implanet's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if Implanet is high growth as no earnings estimate data is available.

Implanet's revenue growth is expected to exceed the United States of America market average.

Unable to compare Implanet's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare Implanet's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Implanet will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Implanet performed over the past 5 years?

4.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Implanet does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Implanet's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Implanet's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Implanet has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Implanet has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Implanet improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Implanet's financial position?


Financial Position Analysis

Implanet is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Implanet's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Implanet's level of debt (108.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (40.4% vs 108.2% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Implanet has less than a year of cash runway based on current free cash flow.

Implanet has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.6% each year.


Next Steps

Dividend

What is Implanet's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Implanet's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Implanet's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Implanet has not reported any payouts.

Unable to verify if Implanet's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Implanet has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Implanet's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average board tenure


CEO

Ludovic Lastennet 0

6.8yrs

Tenure

€294,000

Compensation

Mr. Ludovic Lastennet has been the Chief Executive Officer of Implanet S.A. since November 27,2012 and serves as its Sales & Marketing Director. Mr. Lastennet served as Chief Commercial Officer at Implanet ...


CEO Compensation Analysis

Ludovic's remuneration is lower than average for companies of similar size in United States of America.

Ludovic's compensation has increased whilst company is loss making.


Board Age and Tenure

6.3yrs

Average Tenure

The tenure for the Implanet board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Ludovic Lastennet

    CEO, Sales & Marketing Director and Director

    • Tenure: 6.8yrs
    • Compensation: €294.00k
  • Régis Couëdic

    R&D and RAQA Director

    • Tenure: 0yrs
  • Nicolas Marin

    Marketing Director

    • Tenure: 0yrs
  • David Dieumegard

    Chief Financial Officer

    • Tenure: 4yrs

Board Members

  • Maurizio PetitBon (72yo)

    Non-Voting Member

    • Tenure: 5.8yrs
  • Paula Spears

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: €10.00k
  • Jean-Gérard Galvez

    Chairman

    • Tenure: 8.4yrs
    • Compensation: €108.00k
  • Jan Egberts (61yo)

    Independent Director

    • Tenure: 9.5yrs
    • Compensation: €10.00k
  • Ludovic Lastennet

    CEO, Sales & Marketing Director and Director

    • Tenure: 6.8yrs
    • Compensation: €294.00k
  • Mary Shaughnessy

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: €10.00k

Company Information

Implanet S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Implanet S.A.
  • Ticker: IMPZ.Y
  • Exchange: OTCPK
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €3.684m
  • Listing Market Cap: €4.040m
  • Shares outstanding: 49.12m
  • Website: https://www.implanet.com

Number of Employees


Location

  • Implanet S.A.
  • Technopole Bordeaux Montesquieu
  • Allée François Magendie
  • Martillac
  • Aquitaine
  • 33650
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALIMPENXTPA (Euronext Paris)YesCommon StockFREURNov 2013
IM1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2013
IMPZ.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDMar 2016

Biography

Implanet S.A. provides various spine, knee, and arthroscopy orthopedic implants in France, the United States, Brazil, and internationally. Its products include Jazz systems for a posterior fixation in trau ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/04 01:10
End of Day Share Price2019/06/06 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.